
Opinion|Videos|September 13, 2024
Access Challenges Regarding the Use of Abiraterone in Patients With mCRPC
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Panelists discuss how to address the challenges in providing optimal care for mCRPC patients and how barriers may vary between different healthcare settings, such as rural vs. urban and private vs. public.
Advertisement
Episodes in this series

- mCRPC patients?
- How do you navigate these challenges to ensure patients receive optimal care?
- How might the barriers differ between various health care settings (eg, rural vs urban, private vs public)?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves first-line Zenflow system for the treatment of BPH
2
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC
5

















